Trametinib placebo

DRUG2 trials

Conditions

Differentiated Thyroid Cancer (DTC)Melanoma

Phase 3

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

CompletedNCT01584648

Novartis PharmaceuticalsMelanoma

Start: 2012-05-04End: 2019-02-28Updated: 2021-02-17

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Active, not recruitingNCT04940052

Novartis PharmaceuticalsDifferentiated Thyroid Cancer (DTC)

Start: 2021-11-15End: 2027-05-25Updated: 2026-06-26

2026-07-13

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice

Melanoma Research2023-08-036 citations

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine2023-04-14244 citations

Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.

2021-07-0219 citations

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.

2021-02-1273 citations

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

New England Journal of Medicine2019-06-041314 citations

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Journal of Clinical Oncology2019-05-208 citations

Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).

Journal of Clinical Oncology2019-05-201 citations

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

2017-07-01456 citations

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

2017-06-22131 citations

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

2016-11-16233 citations

Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.

Journal of Clinical Oncology2016-05-2063 citations

Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.

Journal of Clinical Oncology2016-05-208 citations

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

2015-05-31963 citations

Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.

Journal of Clinical Oncology2015-05-205 citations

2015-03-1760 citations

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

New England Journal of Medicine2014-09-291830 citations

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

Journal of Clinical Oncology2014-05-2069 citations

Trametinib placebo

Sponsors

Conditions

Phase 3

Related Papers